KRAS and neoplasm: Christian F Ruiz's team found that mutant KRAS promotes the de novo lipid synthesis and the SREBP1-mediated mitochondrial gene expression in non-small cell lung cancer, and mutant KRAS tumor cells are susceptive to FASN inhibitors.